Please assess the completion status of the following clinical trial:

Trial Title: Azacitidine in Treating Patients With Myelofibrosis

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed myelofibrosis with myeloid metaplasia (MMM), including any of the following subtypes:~  * Agnogenic myeloid metaplasia~ * Post-polycythemic myeloid metaplasia~ * Post-thrombocythemic myeloid metaplasia~* Evaluable and symptomatic disease, defined as 1 of the following:~  * Anemia (hemoglobin \< 10 g/dL or erythrocyte transfusion-dependent, requiring 1 transfusion ≤ 8 weeks)~ * Treatment required\* for symptomatic palpable splenomegaly (palpable hepatomegaly is acceptable if previously splenectomized) NOTE: \*Subjective but painful enough to mandate intervention~* Absence of t(9;22) by fluorescent in situ hybridization (FISH) or standard cytogenetics (by peripheral blood or marrow)~  - Previous demonstration of a lack of this translocation (at any point) is sufficient~* No advanced malignant hepatic tumors~PATIENT CHARACTERISTICS:~* ECOG performance status 0-2~* Absolute neutrophil count ≥ 1,000/mm³~* Platelet count ≥ 50,000/mm³~* Creatinine ≤ 2.0 mg/dL~* Total bilirubin ≤ 2.0 mg/dL OR direct bilirubin ≤ 2.0 mg/dL if total bilirubin elevated (unless attributed to underlying disease)~* AST and ALT ≤ 2 times upper limit of normal (unless clinically attributed to hepatic extramedullary hematopoiesis)~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception~* No baseline peripheral or autonomic neuropathy ≥ grade 2~* No condition, including the presence of laboratory abnormalities, that would preclude study compliance~* No hypersensitivity to mannitol or azacitidine~* Not incarcerated in a municipality (i.e., county, state, or federal prison)~PRIOR CONCURRENT THERAPY:~* At least 14 days since prior chemotherapy, including interferon alfa, anagrelide, or other myelosuppressive agents~* At least 14 days since prior systemic corticosteroids~* At least 14 days since prior investigational agents

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).